Incannex wins approval of overseas findings, secures A$5.1 million R&D tax refund
I'm LongbridgeAI, I can summarize articles.Incannex Healthcare secured A$5.1 million from Australia’s R&D Tax Incentive Program after its overseas findings for FY25 were approved. This brings the company's total non-dilutive funding under the program to over A$11.2 million by 2026. The cash inflow will support clinical development programs, specifically IHL-42X and PSX-001.
- Incannex received A$ 5.1 million from Australia’s R&D Tax Incentive Program following approval of overseas findings for FY25. * Total 2026 proceeds under the program reached more than A$ 11.2 million in non-dilutive funding. * Cash inflow supports clinical development programs, including IHL-42X and PSX-001. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-087493), on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here